Pharmaceuticals

HIV: handling a killer condition

The first AIDS-related deaths began to surface almost 40 years ago in 1981. At that time, we had no effective medication and AIDS was a certain death sentence. At its peak, the AIDS crisis was killing 2 million people each year – people from all corners of society and across the...

Read more

The Influence of Artificial Intelligence on the Pharmaceutical Pipeline

On Wednesday 5th June, Gill Jennings & Every hosted an event to investigate how Artificial Intelligence (AI) and Machine Learning (ML) are transforming digital healthcare and pharmaceuticals.  We brought together an expert panel to help us find out more about the different ways AI is being implemented and their advantages...

Read more

SPCs: Waive goodbye to your protection

In Europe, Supplementary Protection Certificates (SPCs) compensate patentees for the inevitable delay in obtaining Marketing Authorisation by extending exclusivity for a marketable pharmaceutical or plant protection product by up to five years (five-and-a-half years for paediatric medicines) following the expiry of the related patent protection. Earlier this year, the EU...

Read more

Lowering the bar to purity claims

Every so often, the European Patent Office issues a decision on a case which has important consequences for other patent applicants. The recent decision T1085/13 (discussed in greater detail here) has implications for how purity claims are assessed at the EPO and may be seen as patentee-friendly, particularly for the...

Read more

AI Accelerates Innovation

This article was originally posted on Communications of the ACM and remains their copyrighted material. Please visit their website here to read the full article. “To invent, you need a good imagination and a pile of junk.” So said Thomas Edison, America’s most prolific inventor. Yet the march of technology is now changing...

Read more